Prescriptions of GLP-1 receptor agonist drugs for children aged 8 to 11 with obesity rise sharply in the United States, despite the medications not being FDA-approved for that age group. The Independent and MedPage Today report that use increases dramatically over recent years, pointing to a rapid shift toward off-label treatment for pediatric obesity.
According to MedPage Today, an analysis of health data shows prescribing increases by about 310-fold since 2019 for children ages 8 to 11. The outlets also situate the trend within the wider pediatric obesity burden, noting that obesity is common in children and is treated as a chronic condition associated with elevated long-term health risks.
While both outlets describe the same overall pattern—rapid growth in off-label GLP-1 use for under-12s—there are differences in emphasis. The Independent highlights the broader impact of childhood obesity and risk framing, while MedPage Today focuses more directly on the magnitude of prescribing growth and the regulatory status of approvals for younger children.
